About Us

About InterCure, Manufacturer of RESPeRATE

• InterCure Ltd. (Tel-Aviv Stock Exchange: INCR), a medical device company, is successfully selling the world's first, FDA-cleared, non-drug, non-invasive hypertension treatment device RESPeRATE.®
• InterCure has an exciting product pipeline based on its broadly-patented “Device-Guided Breathing” technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
• Headquartered from New York, NY and Lod Israel, InterCure is a publicly traded Israeli company founded in 1994 by Dr. Benjamin Gavish and Erez Gavish. InterCure also operates a marketing office in London, outsourced call centers/warehouses in NJ, Southampton, UK and Saskatchewan, Canada. RESPeRATE itself is produced in Nazareth, Israel.

RESPeRATE Customer Facts

• 90% of RESPeRATE owners are satisfied with the device and are still using it regularly after eight to twelve weeks.
• Two-thirds of owners would definitely recommend RESPeRATE to a friend.
• Already 20% of primary care physicians in the US are aware of RESPeRATE. 6 out of 10 of these physicians recommend the product.
• 90% of RESPeRATE owners are over the age of 50 (equally male and female).
• 2/3 of RESPeRATE owners are on medications, most of whom suffer from side effects and almost all of whom have previously tried diet and exercise to lower their blood pressure.

Source: Ipsos-Vantis market research and on file information

Corporate Milestones

2008

• InterCure signs agreement with Boots UK Limited, the largest pharmacy chain in the UK, for the distribution of the RESPeRATE.
• RESPeRATE Ultra is launched, the company's "smartest" blood pressure treatment device, just half the size of previous models featuring an interactive tutorial.
• Journal of Human Hypertension publishes study demonstrating RESPeRATE's effectiveness in lowering blood pressure for diabetic hypertensive patients.
• InterCure Ltd receives Deloitte Technology Fast 50 and Fast 500 Award.
• Circulation: Heart Failure publishes RESPeRATE clinical study results.
• Warehouse club distribution begins through Costco.com.
• Nationwide retail pharmacy distribution begins at Lloyds Pharmacy in UK.
• Initial distribution begins at CVS Home Health Centers in 8 states.
• Ranked No. 1 website by visits among all US Pharmaceutical and Medical Products (Hitwise Health and Medical survey Q1 2008).
• RESPeRATE attains its 100,000th user.

2007

• InterCure names Scot Dube Vice President of Sales.
• InterCure, Ltd receives Deloitte Technology Fast 50 and Fast 500 Award.
• InterCure and High Tech Health announce RESPeRATE launch into pharmacy market in Australia.
• InterCure and Mashco announce launch into independent pharmacies in the United Kingdom.
• InterCure and Omron Healthcare (UK) Ltd. announce marketing collaboration for hypertension market in United Kingdom.
• On July 26th 2007, InterCure completed its IPO on the Tel Aviv Stock Exchange and raised $16M in common shares and convertible bonds (TASE: INCR).
• California Technology Assessment Forum (CTAF), a program of the Blue Shield of California Foundation, finds RESPeRATE meets its safety and effectiveness criteria.
• 10th clinical study finds RESPeRATE effective in lowering blood pressure for diabetic hypertensives.

2006

• InterCure expands its direct-to-consumer operation in the UK; Print advertising campaign begins in over 100 daily newspapers in the UK and the US.
• RESPeRATE attains its 50,000th user.
• Website becomes the most popular hypertension destination.
• RESPeRATE Duo™ introduced allowing two users to track progress in separate memories (on a single device).
• Distribution agreement for RESPeRATE in Japan.
• Medscape's peer reviewed paper, Med Gen Med, publishes a clinical review of RESPeRATE's seven clinical studies. Eighth & ninth clinical studies confirm RESPeRATE's efficacy in Asians and in the diabetic hypertensive population.

2005

• InterCure awarded Hypertension Treatment Technology Innovation of the year by Frost & Sullivan.
• InterCure focuses on online marketing to promote RESPeRATE in a cost effective manner; Series C investment round secured.

2004

• 10,000 satisfied users; Wall Street Journal & Washington Post rave about RESPeRATE.
• Korean FDA and other key markets clear RESPeRATE. 2003
• RESPeRATE begins selling in the US; Limited funding hinders on product launch.
• Seventh study demonstrates RESPeRATE's therapeutic powers in resistant hypertensive patients. 2002
• FDA clears RESPeRATE for OTC use following successful US-based, multi-center, randomized controlled study (study #6).

2001

• Fourth and fifth clinical studies successfully demonstrate RESPeRATE's efficacy in lowering blood pressure when measured with 24-ambolutory and/or home blood pressure monitors.
• Series B funding secured.
• Scientific Advisory Board is established.

2000

• FDA clears RESPeRATE as a hypertension treatment device under doctors prescription (Rx), based on successful results of three randomized controlled studies.
• InterCure Inc., commences operation in NY after Series A funding is secured.

1997

• InterCure commences operations after seed financing secured.

1994

• InterCure Ltd. is incorporated in Israel.